Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2
|ClinicalTrials.gov Identifier: NCT00273494|
Recruitment Status : Unknown
Verified May 2008 by Rigshospitalet, Denmark.
Recruitment status was: Recruiting
First Posted : January 9, 2006
Last Update Posted : May 22, 2008
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease.
Patients are randomised to surgery or not.
|Condition or disease||Intervention/treatment||Phase|
|Non-Small Cell Lung Cancer||Procedure: Surgery||Phase 3|
Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation.
Endpoint is survival.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||406 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIA/N2 (T1N2, T2N2, T3/N2).|
|Study Start Date :||January 1998|
|Estimated Study Completion Date :||January 2008|
- time to progression
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273494
|Contact: Jens B. Sorensen, MDfirstname.lastname@example.org|
|Dept. Oncology, Rigshospitalet||Recruiting|
|Copenhagen, Denmark, 2100|
|Contact: Jens B. Sorensen, MD 35454372 email@example.com|
|Contact: Jens B. Sorensen, MD 35454372 ext firstname.lastname@example.org|
|Principal Investigator: Jens B. Sorensen, MD|
|Study Chair:||Jens B. Sorensen, MD||Rigshospitalet, Denmark|